Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
There might be a use for Glaxo’s anti-Covid-19 antibody otilimab in old patients, but repeating Actemra’s trick will not be easy.
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.